SPY391.77+4.27 1.10%
DIA319.53+4.14 1.31%
IXIC13,597.97+132.77 0.99%

BRIEF-India Drug Regulator Committee Recommends Phase 2/3 Trial For Novavax-Serum Institute COVID-19 Vaccine

· 02/05/2021 04:05
BRIEF-India Drug Regulator Committee Recommends Phase 2/3 Trial For Novavax-Serum Institute COVID-19 Vaccine

- Central Drugs Standard Control Organization Subject Expert Committee:

  • INDIA DRUG REGULATOR COMMITTEE RECOMMENDS PERMITTING PHASE II/III TRIAL FOR NOVAVAX-SERUM INSTITUTE COVID-19 VACCINE, SUBJECT TO CONDITION - STATEMENT

Source text: (https://bit.ly/39MfJOh)

Further company coverage: NVAX.O


((Reuters.Briefs@thomsonreuters.com;))